Brian Frederick

**** **** ***** **.

Ben Lomond, CA 95005

831-***-****

abmh3g@r.postjobfree.com

Summary

Highly productive, experienced medicinal synthetic chemist, proven

accomplishments in small molecule discovery and peptide conjugate discovery

and development, expertise in molecular design, synthesis and analysis of

biologically active molecules

Technical Skills

Solution and solid phase synthesis and purification of small organic

molecules, peptides and conjugates

Chromatography - column, analytical and prep HPLC, IE, SEC, LC/MS, FPLC

Spectroscopy - NMR, UV/Vis, Fluorescence, CD, IR, DLS

Professional Experience

Intradigm Corp. April 2009 -

May 2010

Scientist

Responsible for synthesis, purification and analysis of polycationic

peptides and their conjugates for evaluation in nanoparticle siRNA

formulations

. Developed conjugation strategies for site specific PEGylation

. Created numerous homing conjugates tethered through PEG to our polycation

carriers for selective tissue delivery

. Synthesized many Polycation-PEG-Lipid constructs

. Chemically modified polycation peptide carrier to alter chem/physical

properties of resulting siRNA nanoparticle

. Developed chromatographic analytical methods, HPLC, IE; utilized

colorimetric UV/fluorescent assays to follow conjugation/derivitization

reactions and evaluate product purity

. Developed fluorescent and biotinylated constructs for use as biological

research tools

. Initiated, set up and employed analytical CRO for AAA analysis

. Worked collaboratively, contributed ideas and presented original data as

part of multidisciplinary Technology Development team

Affymax, Inc., Palo Alto, CA 1999 -

March 2009

Staff Scientist, January 2004 - March 2009

First non-PhD promoted to Staff Scientist in Medicinal Chemistry group,

recognizing my independence in day to day activities, goal setting, analog

design, literature and patent reviews as well as my abilities to work

cooperatively and productively with scientists in other disciplines such as

biology, preclinical, analytical development and manufacturing

Played key role in the discovery and development of HematideTM, a PEGylated

peptide dimer currently in phase III clinical trials for the correction of

anemia

. Developed linker and PEG conjugation strategies that led to the IND

candidate and supporting patents

. Worked on the synthetic process leading to first gram scale batches used

in critical tox and IND enabling animal studies

. Studied the stability of HematideTM in a variety of conditions; proposed

and synthesized many major degradants and process impurities used for

tox. and analytical method validation

. Developed route to C14 radiolabeled HematideTM used for QWBA analysis

. Designed and synthesized many conjugates for basic research, including

fluorescent, biotinylated, discrete PEG and photoaffinity labeled analogs

. Participated in formal characterization of HematideTM, proposed new

characterization test, identified and oversaw contract labs, set up legal

agreements, designed proof-of-principle experiments

Key team member in the development of intranasal ESA

. Worked on team creating analogs of in-house ESA peptide to find minimal

size and charge for functional activity. Succeeded in reducing size of

active peptide dimer by 12 AA while minimizing charged residues

. Made numerous peptide dimer conjugates with a range of PEG sizes and

other functionalities to improve formulation and/or nasal penetration

. Developed a series of (Acyloxy) alkyl carbamate prodrugs conjugates to

mask charge for increased tight junction transport for intranasal

systemic delivery

. Developed synthetic process and delivered multigram batches of peptide

dimer for creation of WRSS and pre-IND enabling animal and toxicology

studies; wrote process description used by CMO for creation of 100 + g of

intranasal IND candidate

Worked on numerous discovery project teams optimizing peptides as

therapeutics in hematology, tissue protection, oncology and immune-mediated

disease programs

. Synthesized and delivered for biological assay hundreds of peptide

analogs, conjugates and constraints

. Proposed and synthesized numerous series of bicyclic peptides using a

variety of ring closing chemistries to restrict conformation

. Proposed and synthesized a series of antiangiogenic peptide conjugates

with RGD and cyclic NGR homing peptides coupled through a variety of

chemistries for localization to the neovasculature

. Outsourced contract work for characterization of compounds using CD, DLS

Affymax, Inc., Continued

Research Associate I-II, 1999 - 2003

. Designed, synthesized and purified small molecule libraries, including

tetramic acids, thiazolidinones, 1,4 dihydropyridines, pyrolidinetriones,

3,4-Dihydropyrimidin-2(1H)-ones, dihydropyrimidines

. Designed novel phosphotyrosine mimetics and their incorporation into

small molecule library scaffolds, for the inhibition of PTP-1B

AMM, Division of Honeywell, Santa Clara, CA

1999

Chemist

Synthesized and characterized hybrid organic/inorganic network polymers in

the development of low dielectric constant spin on glasses for semi-

conductor industry

Education

. M.S., Chemistry, April 1999

Dept. of Chemistry, University of California Santa Cruz

. B.S., Chemistry, June 1994

California Polytechnic State University, San Luis Obispo

Cum laude

Patents, Publications, Presentations and Posters

1. Frederick, Max B., Frederick, Brian, "Substantially environmental-

pollution-free cleaning method and device employing electric energy

and surface physical properties", 630****-****

2. Holmes, C. P., Yin, Q., Zemede, G., Bhandari, A., Dong, Y. S.,

Tumelty, D., Lalonde, G., Palani, B., Schatz, P. J., Wrighton, N. C.,

Dower, W. J., Frederick, B. T., Chakrabarti, A. "Erythropoietin

receptor-binding peptides, peptide derivatives, and dimers for

treatment of diseases", WO2006062685 2006.

3. Holmes, C. P., Yin, Q., Zemede, G., Bhandari, A., Dong, Y. S.,

Tumelty, D., Lalonde, G., Palani, B., Schatz, P. J., Wrighton, N. C.,

Dower, W. J., Frederick, B. T.; Chakrabarti, A. "Peptides that bind to

the erythropoietin receptor, pharmaceutical compositions, and

therapeutic use", WO2006060148 2006.

4. Hembrough, T. A., Holmes, C. P., Yin, Q., Zemede, G. H., Angell, Y.

M., Frederick, B. T., Xu, C. "Compositions and methods for inhibiting

cellular proliferation", WO2007070372 2007.

5. Hembrough, T. A., Holmes, C. P., Yin, Q., Zemede, G. H., Angell, Y.

M., Frederick, B. T., Xu, C. "Compositions and methods for inhibiting

cellular proliferation", US20070203066 2007.

6. Holmes, Christopher P., Yin, Qun, Zemede, Genet, Bhandari, Ashok,

Dong, Yaohua S., Tumelty, David, Lalonde, Guy, Frederick, Brian T.,

Chakrabarti, Anjan, Balu, Palani, Schatz, Peter J., Wrighton, Nicholas

C., Dower, William J. "NOVEL PEPTIDES THAT BIND TO THE ERYTHROPOIETIN

RECEPTOR" 200********-****

7. Holmes, Christopher P., Chakrabarti, Anjan, Frederick, Brian T., Pan,

Yijun, Dong, Yaohua S., Bhandari, Ashok. "NITROGEN-BASED LINKERS FOR

ATTACHING MODIFYING GROUPS TO POLYPEPTIDES AND OTHER MACROMOLECULES"

200********-****

8. Holmes, Christopher P., Yin, Qun, Zemede, Genet, Bhandari, Ashok,

Tumelty, David, Lalonde, Guy, Balu, Palani, Schatz, Peter J., Dower,

William J., Chakrabarti, Anjan, Dong, Yaohua S., Frederick, Brian T.,

Wrighton, Nicholas C. "Novel Peptides that Bind to the Erythropoietin

Receptor" 200********-****

9. Holmes, C. P., Jones, D. G., Frederick, B. T., Dong, L.-C.

"Development of a New ortho-Nitrobenzyl Photolabile Linker for Solid

Phase Synthesis" in Peptides: Chemistry, Structure and Biology,

Proceedings of the 14th Am. Peptide Symposium, Kaumaya, P. T. P.,

Hodges, R. S. eds., Mayflower Scientific: Kingswinford, 1996, pp. 44-

45.

10. Holmes, C. P., Li, X., Pan, Y., Xu, C., Bhandari, A., Moody, C. M.,

Miguel, J. A., Ferla, S. W., DeFrancisco, M. N., Frederick, B. T.,

Zhou, S., Macher, N., Jang, L., Irvine, J. D., Grove, J. R. "Discovery

and structure-activity relationships of novel sulfonamides as potent

PTP1B inhibitors" Bioorg. Med. Chem. Lett. 2005, 15, 4336-4341.

11. Woodburn K.W., Leuther K, Fan Q, Holmes C, Frederick B., Xu C, Wehrman

T, Press R: Renal excretion is the primary route of elimination for

the erythropoiesis stimulating agent Hematide as assessed by

quantitative whole-body autoradioluminography (QWBA) in Sprague Dawley

rats [Abstract SaP333]. Presented at the ERA-EDTA Congress; June 21-

24, 2007; Barcelona, Spain

12. Holmes, C. P., Li, X., Pan, Y., Xu, C., Bhandari, A., Moody, C. M.,

Miguel, J. A., Ferla, S. W., De Francisco, M. N., Frederick, B. T.,

Zhou, S., Macher, N., Jang, L., Irvine, J. D., Grove J. R. "PTP1B

Inhibitors: Synthesis and Evaluation of Difluoro-methylenephosphonate

Bioisosteres on a Sulfonamide Scaffold" Bioorg. Med. Chem. Lett. 2008,

18, 2719-2724.

13. Y. M. Angell, A. Bhandari, A. Chakrabarti, M. N. De Francisco, A. N.

Duguay, B. T. Frederick, K. Leu, K. Leuther, X. Li, K. Penta, S.

Piplani, R. Sana, E. A. Whitehorn, P. J. Schatz, K. Yin, and C. P.

Holmes "Discovery and Optimization of a TRAIL R2 Agonist for Cancer

Therapy", Understanding Biology Using Peptides: Proceedings of the

American Peptide Symposium, 19th, San Diego, 2005.

14. Y. M. Angell, A. Bhandari, A. Chakrabarti, M. N. De Francisco, A. N.

Duguay, B. T. Frederick, K. Leu, K. Leuther, X. Li, K. Penta, S.

Piplani, R. Sana, E. A. Whitehorn, P. J. Schatz, K. Yin, and C. P.

Holmes "Update on the Discovery and Optimization of a TRAIL R2 Agonist

for Cancer Therapy", Peptides for Youth: Proceedings of the American

Peptide Symposium, 20th, Montreal, Quebec, Canada, 2007, 101 -103.

15. Daniel E. Levy, Brian Frederick, Zhongli Ding, Bing Luo, Samuel

Zalipsky. "Nanoparticle-Based Delivery of siRNA" DL invited lecture

at upcoming 240th ACS National Meeting, Boston MA, August 25, 2010

Formal references are available upon request. Please visit my LinkedIn

profile for recommendations from former colleagues.

Contact this candidate